Screener
Palvella Therapeutics PVLA Pre-Tax Income
Pre-Tax Income at other companies
Other financials
Where this comes from
Reported directly by Palvella Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest.
The source filing: Palvella Therapeutics’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 8:30 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-210463
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Fair value adjustments on derivative liabilities – contingent value right liability | 202 | — |
| Interest income, net | 1,073 | 752 |
| Other income (expense), net | (32) | 224 |
| Loss before income taxes | (15,767) | (8,185) |
| Income tax benefit (expense) | — | — |
| Net loss | $(15,767) | $(8,185) |
| Other comprehensive loss: | ||
| Unrealized gain on investments | 4 | — |
Item 1. Financial Statements.
FAQ
- What is Palvella Therapeutics's pre-tax income?
- Palvella Therapeutics (PVLA) reported pre-tax income of -$15.77M in Q1 2026.
- How has Palvella Therapeutics's pre-tax income changed year-over-year?
- Palvella Therapeutics's pre-tax income decreased by 92.6% year-over-year, from -$8.19M to -$15.77M.
- What is the long-term trend for Palvella Therapeutics's pre-tax income?
- Over 2 years (2021 to 2025), Palvella Therapeutics's pre-tax income has grown at a -4.5% compound annual growth rate (CAGR), from -$45.74M to -$41.72M.
- What does pre-tax income mean?
- Total income from all sources — operating income plus non-operating items like interest income, investment gains, and other income — before the provision for income taxes.
Ask your AI about Palvella Therapeutics's pre-tax income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude